Literature DB >> 12015813

Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1-40): the role of salt bridges.

Nicholas M Bentley1, Mary Jo Ladu, Chandrika Rajan, Godfrey S Getz, Catherine A Reardon.   

Abstract

Of the three major isoforms of human apolipoprotein E (apoE), apoE4 is a risk factor for the development of Alzheimer's disease. Among possible neurologically relevant differences in the properties of apoE3 and apoE4 is the fact that apoE3 forms an SDS-stable complex with beta-amyloid-(1-40) (Abeta40) with greater avidity than does apoE4. This interaction may sequester potentially toxic species of Abeta or facilitate clearance. To understand more about this difference, we examined whether differences in salt bridges between apoE domains influence the capacity of apoE isoforms to form complexes with Abeta. In apoE3 there is a salt bridge between Arg-61 and Asp-65, while in apoE4 there are salt bridges between Arg-61 and Glu-255, and Arg-112 and Glu-109. Mutation of position 112, which is Cys in apoE3 and Arg in apoE4, to Ala or Lys abolished complex formation, while mutant apoE with Ser at this position retained the capacity to form complex. Substituting Ala for Glu-109 had no effect on the ability of either apoE4 or apoE3 to form complexes. On the other hand, substitution of Thr for Arg-61 in apoE3 abolished, and truncation of apoE3 at position 201 substantially lowered, but did not abolish, complex formation. Neither of these mutations within apoE4 had any affect on its complex formation with Abeta. These results suggest that the nature of the cysteine residue in apoE3 and interactions between the N-terminal and C-terminal domains of human apoE are important for the ability of apoE3 to form an SDS-stable complex with Abeta40.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12015813      PMCID: PMC1222763          DOI: 10.1042/BJ20020207

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains.

Authors:  L P Aggerbeck; J R Wetterau; K H Weisgraber; C S Wu; F T Lindgren
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

2.  Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins.

Authors:  A Steinmetz; C Jakobs; S Motzny; H Kaffarnik
Journal:  Arteriosclerosis       Date:  1989 May-Jun

Review 3.  Apolipoprotein E: structure-function relationships.

Authors:  K H Weisgraber
Journal:  Adv Protein Chem       Date:  1994

4.  Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain.

Authors:  D B Carter; E Dunn; D D McKinley; N C Stratman; T P Boyle; S L Kuiper; J A Oostveen; R J Weaver; J A Boller; M E Gurney
Journal:  Ann Neurol       Date:  2001-10       Impact factor: 10.422

5.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

6.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

Authors:  A M Saunders; W J Strittmatter; D Schmechel; P H George-Hyslop; M A Pericak-Vance; S H Joo; B L Rosi; J F Gusella; D R Crapper-MacLachlan; M J Alberts
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

7.  Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.

Authors:  K H Weisgraber
Journal:  J Lipid Res       Date:  1990-08       Impact factor: 5.922

8.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Authors:  D E Schmechel; A M Saunders; W J Strittmatter; B J Crain; C M Hulette; S H Joo; M A Pericak-Vance; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

9.  Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms.

Authors:  L M Dong; C Wilson; M R Wardell; T Simmons; R W Mahley; K H Weisgraber; D A Agard
Journal:  J Biol Chem       Date:  1994-09-02       Impact factor: 5.157

10.  Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system.

Authors:  J K Boyles; R E Pitas; E Wilson; R W Mahley; J M Taylor
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more
  14 in total

1.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE)-amyloid beta complexes depends on ApoE isoform and cell type.

Authors:  Eleanna Kara; Jordan D Marks; Allyson D Roe; Caitlin Commins; Zhanyun Fan; Maria Calvo-Rodriguez; Susanne Wegmann; Eloise Hudry; Bradley T Hyman
Journal:  J Biol Chem       Date:  2018-06-27       Impact factor: 5.157

3.  Binding of apolipoprotein E inhibits the oligomer growth of amyloid-β peptide in solution as determined by fluorescence cross-correlation spectroscopy.

Authors:  Sonny Ly; Robin Altman; Jitka Petrlova; Yu Lin; Silvia Hilt; Thomas Huser; Ted A Laurence; John C Voss
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

4.  ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions.

Authors:  Philip B Verghese; Joseph M Castellano; Kanchan Garai; Yinong Wang; Hong Jiang; Aarti Shah; Guojun Bu; Carl Frieden; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-25       Impact factor: 11.205

5.  Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.

Authors:  Leon M Tai; Tina Bilousova; Lisa Jungbauer; Stephen K Roeske; Katherine L Youmans; Chunjiang Yu; Wayne W Poon; Lindsey B Cornwell; Carol A Miller; Harry V Vinters; Linda J Van Eldik; David W Fardo; Steve Estus; Guojun Bu; Karen Hoppens Gylys; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

Review 6.  The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD.

Authors:  Sally Hunter; Thomas Arendt; Carol Brayne
Journal:  Mol Neurobiol       Date:  2013-04-03       Impact factor: 5.590

7.  An umbraviral protein, involved in long-distance RNA movement, binds viral RNA and forms unique, protective ribonucleoprotein complexes.

Authors:  Michael Taliansky; Ian M Roberts; Natalia Kalinina; Eugene V Ryabov; Shri Krishna Raj; David J Robinson; Karl J Oparka
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

8.  A differential association of Apolipoprotein E isoforms with the amyloid-β oligomer in solution.

Authors:  Jitka Petrlova; Hyun-Seok Hong; Daniel A Bricarello; Ghimire Harishchandra; Gary A Lorigan; Lee-Way Jin; John C Voss
Journal:  Proteins       Date:  2011-02

9.  Role of Apolipoprotein E in β-Amyloidogenesis: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO FIBRIL CONVERSION OF Aβ IN VITRO AND BRAIN Aβ DEPOSITION IN VIVO.

Authors:  Yukiko Hori; Tadafumi Hashimoto; Hidetoshi Nomoto; Bradley T Hyman; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

Review 10.  Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.

Authors:  Lorenzo M Refolo; Howard M Fillit
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.